Life Sciences Forum Presented by ICON and the Irish American Business Chamber & Network

Life Sciences Forum

Thurs. November, 16th, 1:30pm - 5pm

Innovation and the Financial Impact Along the Drug Development Path

ICON will host in collaboration with the Irish American Business Chamber the Network Life Sciences Forum. Innovation often starts the drug discovery process, but innovation also inspires change in development, manufacturing, supply chain, and drug delivery in nearly every step of the drug development continuum. The financial impact can also be seen at all levels of development. The debate over rising drug prices has become a heated debate. Who is responsible for high drug pricing?

The panel discussion will be moderated by ICON’s VP of Imaging, Paul McCracken and will give attendees a detailed, behind-the-scenes reality of bringing a new drug to market, from concept to patient delivery, and how innovative discoveries have impacted this pathway. 

Paul McCracken Ph.D, Vice President, Medical Imaging, ICON plc. 

Dr. Paul McCracken has over 20 years’ experience in imaging and pharmaceuticals, with a strong track record of applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas. Dr. McCracken joined ICON from Eisai, where he led the Imaging Centre of Excellence, which drives novel approaches for discovery targets and translational biomarkers, primarily through the introduction of imaging genetics and the acceleration of novel PET approaches. Prior to Eisai, Paul worked at Merck Research Laboratories, where he developed preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities. Dr. McCracken holds a Bachelor of Science in Physics from The College of New Jersey, a Master of Science in Physics/Medical Physics from Wright State University and received his Ph.D. in Biomedical Engineering – Imaging from the Mayo Clinic College of Medicine.

Featured Panelists:

Dr. Garret FitzGerald, Director, Institute for Translational Medicine & Therapeutics, University of Pennsylvania

Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Systems Pharmacology and Translational Therapeutics and directs the Institute for Translational Medicine and Therapeutics. Dr. FitzGerald’s work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs.

Dr. Andrea Perrone , MD Associate Vice President, Clinical Imaging Translational Medicine, Merck & Co

Andrea Perrone, MD, is currently the Associate Vice President of Clinical Imaging in Translational Medicine. She and her team provide imaging expertise in protocol development, execution and regulatory support for clinical trials of therapeutic agents across all disease indications. 


Joseph Sirianni, Senior Director Global Engineering Services, Zoetis

Joseph Sirianni is currently the Senior Director Global Engineering at Zoetis. He was responsible for the design of the global function and instrumental in the evaluation of the Pfizer Animal Health Engineering Organization, development of the Engineering support model for Zoetis including the separation of manufacturing operations from Pfizer. At Zoetis he leads a group of technical experts that guide the execution of capital investments, bring technologies to manufacturing for new products and enabling efficient manufacturing processes. 

Sponsored by Aer Lingus.